Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Text Messaging for Adherence in Adolescent Liver Transplant Recipients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Rebecca Berquist McKenzie, Stanford University
ClinicalTrials.gov Identifier:
NCT01696331
First received: September 27, 2012
Last updated: November 24, 2015
Last verified: November 2015
  Purpose
Text message reminders will improve adherence to lab tests in adolescent liver transplant recipients.

Condition Intervention
Liver Transplant
Adherence
Behavioral: Text Message Reminder

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Impact of Text Messaging on Adherence in Adolescent Liver Transplant Patients

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Adherence to lab tests [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Texting responses [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Correspondence between actual completion of tests versus reported


Enrollment: 42
Study Start Date: September 2012
Estimated Study Completion Date: December 2016
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Text Message Reminder Behavioral: Text Message Reminder
Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.

Detailed Description:
Adolescent patients who received a liver transplant will be recruited to participate in receiving text message reminders for lab tests. They will be send de-identified messages according to their required lab schedule. The investigators will monitor their adherence to lab tests as well as medication and clinic visits. They will also have a questionnaire about their medical regimen before and at the end of the study.
  Eligibility

Ages Eligible for Study:   12 Years to 25 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient >12 years
  • Received liver transplant
  • Followed by Stanford Liver Transplant Team

Exclusion Criteria:

  • No personal cell phone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01696331

Locations
United States, California
Lucile Packard Children's Hospital
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Stanford University
  More Information

Responsible Party: Rebecca Berquist McKenzie, Clinical Instructor, Department of Pediatric Gastroenterology, Stanford University
ClinicalTrials.gov Identifier: NCT01696331     History of Changes
Other Study ID Numbers: 25318 
Study First Received: September 27, 2012
Last Updated: November 24, 2015
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on September 30, 2016